How Is LABA-ICS Combination Therapy Reshaping Asthma and COPD Management?
Long-acting beta-2 adrenoceptor agonist and inhaled corticosteroid combination therapy — the cornerstone pharmacological approach for moderate-to-severe asthma and COPD combining bronchodilator (LABA: salmeterol, formoterol, vilanterol, indacaterol) and anti-inflammatory (ICS: fluticasone, budesonide, beclomethasone, mometasone) mechanisms in a single inhaler device — representing...